Waldenstrom's Macroglobulinemia Recurrent

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Waldenstrom's Macroglobulinemia Recurrent trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 1

NCT06712810

Q702 for the Treatment of Patients With Hematologic Malignancies

This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications c…

United States46 participantsStarted 2025-08-27

Treatment: Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection

All recent trials (27 shown)

TerminatedPhase 2

NCT03506373

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

This phase II trial studies the side effects of ibrutinib citrate when given with ixazomib, and determines how well they work in treating patients with Waldenst…

United States21 participantsStarted 2018-08-14

Treatment: Ibrutinib, Ixazomib Citrate

Not Yet RecruitingPhase 1/2

NCT07420959

ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia

This phase I/II trial studies the side effects and best dose of ABBV-383 and to see how well it works in treating patients with Waldenström macroglobulinemia th…

United States38 participantsStarted 2026-03-25

Treatment: Biospecimen Collection, Bone Marrow Aspiration

Waldenstrom's Macroglobulinemia Recurrent

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Q702 for the Treatment of Patients With Hematologic Malignancies

All recent trials (27 shown)

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Q702 for the Treatment of Patients With Hematologic Malignancies

All recent trials (27 shown)

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrut…

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilize…

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL

A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic…

Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or M…

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Wa…

LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia

Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia

Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma